Stock Ratings / Health Care / SINT / financials

GUTS (52) CNSY (36) CTSO (21) ICU (33) ⌘ Pro Terminal →

SiNtx Technologies Inc. (SINT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.72 -1.15% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.71

SiNtx Technologies Inc. (SINT) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $13.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.71 (-0.40%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SINT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY SINT SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (22% of score)

FRED Regime × Technicals: 10% of 52W Range • RSI-14 at 43.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$2.11-17.5% Next Q

Q2 (-2Q)

Grade D$1.74-9.2% Next Q

Q3 (-1Q)

Grade D$1.58+8.9% Next Q

Current

Grade D-$1.72-8.1% Hist 90D α

Trajectory: D (45) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SINT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SINT currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.79) and Max Pain ($1.81) forces dealer call-delta covering toward $4.68.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SINT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SINT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How SINT Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $2.6M

FY24

Rev $2.9M

FY25

Rev $1.0M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$1.0M	45.3%	-80%	-$10.4M	-$8.8M	-45%
FY 2024	$2.9M	71.9%	-80%	-$11.0M	-$9.3M	-45%
FY 2023	$2.6M	45.3%	-80%	-$8.3M	-$14.1M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SINT)

✓Walkthrough of SINT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SINT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.48%📐 WEDGE COMPRESSION COIL

2026-10-30O $1.70H $1.72L $1.68C $1.72VOL 4.7K

RES: $2.37SUP: $1.56SMA50: $1.79SMA200: $2.23

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SINT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SINT Butterfly Map → + Track SINT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -64.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SINT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SINT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SINT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SINT)

Health Care Rank #763 of 1016 ⚔️ GUTS vs SINT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SINT vs. GUTS, CNSY, CTSO, ICU)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, SiNtx Technologies Inc. (SINT) ranks #763 by composite RQD confidence (37/100, grade D-) and #870 by equity capitalization ($13.0M). Within this direct 5-issuer industry benchmark cohort, SINT leads on earnings valuation at N/A trailing P/E, while SINT leads on capital efficiency and profitability with -35.0% ROIC and 45.3% gross margin. GUTS currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with SINT at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SINT ACTIVE SiNtx Technologies Inc.	D-	37/100	—	45.3%	-35.0%	-1.15%	$13.0M	Benchmark Subject
GUTS Fractyl Health Inc.	D+	52/100	—	—	-35.0%	+11.40%	$13.2M	/guts-vs-sint →
CNSY Cerenome Inc.	D-	36/100	—	—	-35.0%	0.00%	$13.2M	/cnsy-vs-sint →
CTSO Cytosorbents Corporation	E	21/100	—	71.5%	-35.0%	-16.03%	$13.9M	/ctso-vs-sint →
ICU SeaStar Medical Holding Corporation	E	33/100	—	95.7%	-35.0%	-6.85%	$12.2M	/icu-vs-sint →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001269026

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SiNtx Technologies Inc. (SINT) reported GAAP revenue of $1.0M (-64.7% vs. FY2024 revenue of $2.9M , and -61.2% cumulative change since FY2023) , GAAP net income of -$10.4M, operating cash flow of -$8.6M, and free cash flow of -$8.8M (+6.2% YoY). On the balance sheet, SINT closed FY2025 with $9.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.0M	-$10.4M	-$8.6M	-$8.8M	$9.5M	—
FY2024 (FY)	2024-12-31	$2.9M	-$11.0M	-$8.6M	-$9.3M	$9.4M	—
FY2023 (FY)	2023-12-31	$2.6M	-$8.3M	-$14.1M	-$14.1M	—	—

3. SINT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SINT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, SiNtx Technologies Inc. (NASDAQ: SINT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.72 (-1.15% 1D, market cap $13.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SINT ranks #763 in composite RQD confidence.

How does SINT compare to GUTS and CNSY in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), SINT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 45.3%, and ROIC of -35.0%. By comparison, GUTS (Fractyl Health Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -35.0%, cap $13.2M) and CNSY (Cerenome Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $13.2M). Among the 5-stock peer group, SINT leads on earnings multiple (N/A) while SINT leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SINT?

Per SINT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001269026), SiNtx Technologies Inc. generated $1.0M in revenue (-64.7% YoY), -$10.4M in net income, and -$8.8M in free cash flow against $9.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SINT trading relative to its 50-day, 200-day, and 52-week technical levels?

SINT last traded at $1.72 (-1.15% on volume of 9,469 shares), positioning the stock -3.91% below its 50-day simple moving average ($1.79) and -22.87% below its 200-day simple moving average ($2.23). Across its 52-week range of $1.40 to $4.46, SINT sits at the 10.5% percentile with a 14-day RSI of 43.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.51 to $1.93).